Durham, NC – According to filings with the U.S. Securities and Exchange Commission, IMMvention Therapeutix is raising $6,899,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Anil Goyal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IMMvention Therapeutix
Discovering and developing first-in-class novel small molecule pan-inflammasome inhibitors for treating inflammatory diseases. Developer of small molecule pan-inflammasome inhibitors designed to treat inflammatory diseases. The companys inhibitors offer proprietary technology that delivers innate immunomodulatory drugs to immune cells, illness-modifying therapies inhibit inflammation caused by inflammasomes that activate inflammatory responses, enabling patients to cure autoimmune conditions.

To learn more about IMMvention Therapeutix, visit http://immventionthera.com/

Contact:
Anil Goyal, Chief Executive Officer
919-593-6230
anil@immventionthera.com
https://www.linkedin.com/in/goyalanilk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved